283
views
0
recommends
+1 Recommend
0 collections
    8
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Crystal structure of the μ-opioid receptor bound to a morphinan antagonist

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          Opium is one of the world’s oldest drugs, and its derivatives morphine and codeine are among the most used clinical drugs to relieve severe pain. These prototypical opioids produce analgesia as well as many of their undesirable side effects (sedation, apnea and dependence) by binding to and activating the G-protein-coupled μ-opioid receptor (μOR) in the central nervous system. Here we describe the 2.8 Å crystal structure of the μOR in complex with an irreversible morphinan antagonist. Compared to the buried binding pocket observed in most GPCRs published to date, the morphinan ligand binds deeply within a large solvent-exposed pocket. Of particular interest, the μOR crystallizes as a two-fold symmetric dimer through a four-helix bundle motif formed by transmembrane segments 5 and 6. These high-resolution insights into opioid receptor structure will enable the application of structure-based approaches to develop better drugs for the management of pain and addiction.

          Related collections

          Most cited references51

          • Record: found
          • Abstract: found
          • Article: not found

          Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists.

          Chemokine receptors are critical regulators of cell migration in the context of immune surveillance, inflammation, and development. The G protein-coupled chemokine receptor CXCR4 is specifically implicated in cancer metastasis and HIV-1 infection. Here we report five independent crystal structures of CXCR4 bound to an antagonist small molecule IT1t and a cyclic peptide CVX15 at 2.5 to 3.2 angstrom resolution. All structures reveal a consistent homodimer with an interface including helices V and VI that may be involved in regulating signaling. The location and shape of the ligand-binding sites differ from other G protein-coupled receptors and are closer to the extracellular surface. These structures provide new clues about the interactions between CXCR4 and its natural ligand CXCL12, and with the HIV-1 glycoprotein gp120.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene.

            Despite tremendous efforts in the search for safe, efficacious and non-addictive opioids for pain treatment, morphine remains the most valuable painkiller in contemporary medicine. Opioids exert their pharmacological actions through three opioid-receptor classes, mu, delta and kappa, whose genes have been cloned. Genetic approaches are now available to delineate the contribution of each receptor in opioid function in vivo. Here we disrupt the mu-opioid-receptor gene in mice by homologous recombination and find that there are no overt behavioural abnormalities or major compensatory changes within the opioid system in these animals. Investigation of the behavioural effects of morphine reveals that a lack of mu receptors abolishes the analgesic effect of morphine, as well as place-preference activity and physical dependence. We observed no behavioural responses related to delta- or kappa-receptor activation with morphine, although these receptors are present and bind opioid ligands. We conclude that the mu-opioid-receptor gene product is the molecular target of morphine in vivo and that it is a mandatory component of the opioid system for morphine action.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function.

              The beta2-adrenergic receptor (beta2AR) is a well-studied prototype for heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors (GPCRs) that respond to diffusible hormones and neurotransmitters. To overcome the structural flexibility of the beta2AR and to facilitate its crystallization, we engineered a beta2AR fusion protein in which T4 lysozyme (T4L) replaces most of the third intracellular loop of the GPCR ("beta2AR-T4L") and showed that this protein retains near-native pharmacologic properties. Analysis of adrenergic receptor ligand-binding mutants within the context of the reported high-resolution structure of beta2AR-T4L provides insights into inverse-agonist binding and the structural changes required to accommodate catecholamine agonists. Amino acids known to regulate receptor function are linked through packing interactions and a network of hydrogen bonds, suggesting a conformational pathway from the ligand-binding pocket to regions that interact with G proteins.
                Bookmark

                Author and article information

                Journal
                0410462
                6011
                Nature
                Nature
                Nature
                0028-0836
                1476-4687
                8 May 2012
                21 March 2012
                16 December 2012
                : 485
                : 7398
                : 321-326
                Affiliations
                [1 ]Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, California 94305, USA.
                [2 ]Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA.
                [3 ]Laboratori de Medicina Computacional, Unitat de Bioestadística, Universitat Autònoma de Barcelona, Barcelona, Spain.
                [4 ]Department of Structural Biology, Stanford University School of Medicine, Stanford, California 94305, USA.
                [5 ]CNRS UMR 5203, and INSERM U661, and Université Montpellier 1 et 2, Institut de Génomique Fonctionnelle, Montpellier, 34094, France.
                Author notes
                [# ]Correspondence and requests for materials should be addressed to S.G. ( granier@ 123456stanford.edu ) or B.K.K. ( kobilka@ 123456stanford.edu )
                Article
                NIHMS356247
                10.1038/nature10954
                3523197
                22437502
                c0fa46f5-4176-41cd-9c0b-6f7f8a2d01d7

                Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Funding
                Funded by: National Institute on Drug Abuse : NIDA
                Award ID: R21 DA031418 || DA
                Funded by: National Institute of General Medical Sciences : NIGMS
                Award ID: R01 GM083118 || GM
                Categories
                Article

                Uncategorized
                Uncategorized

                Comments

                Comment on this article